Koyfin Home > Directory > Health Care > Adamas Pharma > EBITDA

Adamas Pharma EBITDA Chart (ADMS)

Adamas Pharma annual/quarterly EBITDA from 2012 to 2020. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Adamas Pharma EBITDA for the quarter ending June 06, 2020 was $-7m a -184.23% increase of 13m year over year
  • Adamas Pharma EBITDA for the last 12 months ending June 06, 2020 was $-61m a -51.43% increase of 32m year over year
  • Adamas Pharma Annual EBITDA for 2019 was $-89m a -27.43% increase of 24m from 2018
  • Adamas Pharma Annual EBITDA for 2018 was $-114m a 23.60% decrease of -27m from 2017
  • Adamas Pharma Annual EBITDA for 2017 was $-87m a 30.64% decrease of -27m from 2016
Other Income Statement Metrics:
  • Adamas Pharma Net Income for the quarter ending December 12, 2018 was $-29m a -21.08% increase of 6m year over year
  • Adamas Pharma Total Revenue for the quarter ending September 09, 2018 was $11m a 94.65% increase of 10m year over year
View Chart On Koyfin

Quarterly ADMS EBITDA Data

06/2020$-7m
03/2020$-13m
12/2019$-21m
09/2019$-20m
06/2019$-21m
03/2019$-26m
12/2018$-25m
09/2018$-28m
06/2018$-30m
03/2018$-31m

Annual ADMS EBITDA Data

2019$-89m
2018$-114m
2017$-87m
2016$-60m
2015$-57m
2014$19m
2013$57m
2012$20m
2011$-8m